Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Investments (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Long-Term Investments for 12 consecutive years, with $2.4 million as the latest value for Q2 2025.

  • On a quarterly basis, Long-Term Investments changed N/A to $2.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $2.4 million, a N/A change, with the full-year FY2024 number at $2.3 million, changed N/A from a year prior.
  • Long-Term Investments was $2.4 million for Q2 2025 at Theravance Biopharma, up from $2.3 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $148.2 million in Q2 2022 to a low of $2.3 million in Q4 2024.
  • A 5-year average of $40.9 million and a median of $19.4 million in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: soared 384.12% in 2022, then crashed 80.05% in 2023.
  • Theravance Biopharma's Long-Term Investments stood at $45.1 million in 2021, then surged by 228.82% to $148.2 million in 2022, then crashed by 87.33% to $18.8 million in 2023, then tumbled by 87.79% to $2.3 million in 2024, then increased by 3.18% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Long-Term Investments are $2.4 million (Q2 2025), $2.3 million (Q1 2025), and $2.3 million (Q4 2024).